INTRODUCTION
============

Improved treatment modalities for childhood cancers have increased 5-year survival rates to nearly 80%.[@B1][@B2] However, complications may arise later in the lives of childhood cancer survivors who received cytotoxic drugs, radiation, or other treatments. Due to the increasing number of long-term survivors, these late effects have become an important issue in childhood cancer management.[@B3] Endocrine-related late effects are commonly reported, of which thyroid disorders are the most frequent.[@B4]

Thyroid hormones play an important role in growth and development during childhood. The thyroid is especially radiosensitive, and irradiation of the neck, head, or brain can cause thyroid dysfunction.[@B4][@B5] Recent reports demonstrate that childhood cancer survivors who received total body irradiation, mantle irradiation for Hodgkin disease (HD), craniospinal irradiation for brain tumors, or other conditioning regimens are at risk for thyroid disease.[@B4][@B5][@B6]

The most common thyroid disease of childhood cancer survivors is hypothyroidism.[@B5][@B7] There are two types of hypothyroidism, characterized as follows: primary hypothyroidism, with elevated levels of serum thyroid-stimulating hormone (TSH); and secondary or central hypothyroidism, with reduced levels of circulating TSH. Primary hypothyroidism can be overt \[reduced levels of free thyroxine (fT4) and triiodothyronine (T3)\] or subclinical (normal fT4 and T3 levels). In central hypothyroidism, the reduced thyroid hormone levels result from inadequate stimulation of the thyroid gland due to reduced TSH in cases where hypothalamic-pituitary disturbance is present.[@B8][@B9][@B10] Overt hypothyroidism is usually treated via daily administration of thyroxine pills,[@B8][@B9][@B10] and the distinction between it and subclinical hypothyroidism (SCH) is determined via biochemical measurement of fT4 and T3 concentrations in serum. There is no standard management for patients with SCH and mildly high serum TSH concentrations, although treatment of patients with concentrations of 10 mU/L or more is recommended.[@B8][@B9][@B10]

Pediatric endocrinologists are undecided as to how to treat children with SCH, as controlled pediatric SCH studies are rare. Two recent studies reported that untreated patients with SCH had normal TSH levels at follow-up.[@B10][@B11] However, elucidation of the natural history of SCH as a late effect in childhood cancer survivors is lacking, despite its frequent occurrence in such survivors.[@B12][@B13]

The aim of this study was to determine which children are at risk for persistent SCH after cancer treatment and who therefore should be treated early during the follow-up period.

MATERIALS AND METHODS
=====================

Study population
----------------

Starting in 2005, we established a long-term follow-up clinic at the Yonsei Cancer Center, Yonsei University Health System, Korea to evaluate cancer survivors once or twice a year.[@B7] In accordance with published guidelines, survivors were defined as individuals with no evidence of cancer for 2 or more years after the completion of cancer treatment.[@B14] Among the more than 700 registered survivors in the clinic, 423 had been tested for thyroid function, and seven showed hyperthyroidism (three overt and four subclinical) at 2 years after cancer treatment. The remainder (n=416) included survivors of leukemia (162, 38.9%); non-Hodgkin lymphoma (NHL; 47, 11.3%); HD (12, 2.9%); brain or nasopharyngeal cancer (brain/naso; 43, 10.3%); Wilms tumor (WT), neuroblastoma (NB), or abdominal malignancies including hepatoblastoma (WT/NB/abdomen; 79, 19.0%); and sarcoma or other non-abdominal malignancies (sarcoma/others; 73, 17.5%). Two years after completion of cancer treatment, 300 survivors (72.1%) had normal thyroid function, 12 (2.9%) had overt hypothyroidism, and 104 (25.0%) had SCH. Twelve of the survivors with SCH were lost to follow-up; therefore, 92 survivors with SCH were ultimately included in this study. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System (4-2015-0016).

Thyroid function test and follow-ups
------------------------------------

Serum T3, fT4, and TSH levels were monitored in the survivors; the reference values were 80--200 ng/dL, 0.95--2.23 ng/dL, and 0.3--4.0 mU/L, respectively, as defined by our institution. SCH was defined as a condition in which TSH levels were higher than the reference value and T3 and T4 levels were within the range of the reference values. To detect thyroid disorders in survivors, the thyroid function test (TFT) was performed 2 years after cancer treatment completion as a baseline test.[@B7] Survivors with no thyroid disease-related symptoms received no additional TFTs as routine surveillance to comply with the Korean health insurance policy. Survivors with abnormal thyroid function were followed-up annually or biannually. If thyroid function became normal, they were designated as \"normalized.\" If it did not, they were designated as \"persistent.\"

As recommended by an endocrinologist, thyroid hormone (levothyroxine) was prescribed for survivors whose TSH levels were \>8--10 mU/L, with consideration of their clinical symptoms, signs, and developmental stage. Thyroid hormone replacement was tapered out after 6--12 months. If the TSH level increased after tapering or discontinuing the treatment, the treatment was reinitiated. Thyroid function was monitored every 1--2 years after short-term discontinuation of replacement therapy. If the therapy was permanently discontinued, the survivor was considered to be normalized.

Definitions and variables
-------------------------

The six cancer diagnosis groups were leukemia, NHL, HD, brain/naso, WT/NB/abdomen, and sarcoma/others. We reviewed the treatment modalities, including chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). The types of chemotherapeutic agents used were also reviewed, as were radiation body sites and doses. The total radiation dose per survivor was defined as the maximum total dose of radiation at a specific radiation site. If a survivor had received craniospinal irradiation long after prophylactic brain radiation, we summed the doses at each site and calculated the maximum dose for each site.

The time variables were as follows: age at diagnosis, age at cancer treatment completion, age at the initial TFT (the age at which thyroid function was first categorized after treatment completion), age at the final TFT, and follow-up period (time from the initial TFT to the final TFT).

Statistical analysis
--------------------

Categorical variables including diagnoses and treatment modalities were evaluated by using the chi-square test or Fisher\'s exact test. Continuous variables including time variables and radiation doses were assessed by using Student\'s t-test or an analysis of variance for parametric tests and the Mann-Whitney U-test or Kruskal Wallis test for non-parametric tests. Paired variables were tested using the Wilcoxon signed rank test. The cumulative incidence of thyroid function normalization was assessed in each cancer diagnosis group by using a Kaplan-Meier analysis and the log-rank test. For the Kaplan-Meier analysis and regression analysis, diagnosis groups were categorized into three groups: brain/naso, lymphoma, and other tumors. Variables that were significant in a univariate analysis, including treatment modalities and age at diagnosis, were included in the multivariable model. We calculated the odds ratios using logistic regression after adjustment for the risk factors of persistent SCH including age, gender, HSCT, head radiation, neck radiation, and chemotherapeutic agents such as enzymes and epipodophyllotoxins. All statistical analyses were performed by using SPSS version 21 for Windows (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Patient demographics
--------------------

Two years after cancer treatment completion, 116 of the 423 childhood cancer survivors initially surveyed (27.4%) had hypothyroidism; 112 (26.5%) had primary hypothyroidism, and four (0.94%) had secondary hypothyroidism. The four survivors with secondary hypothyroidism were brain tumor survivors, and all were cases of overt hypothyroidism. Eight of the 112 (7.1%) survivors with primary hypothyroidism had overt hypothyroidism, whereas 104 (92.9%) had SCH. Six of the eight (75%) survivors with overt hypothyroidism were brain tumor survivors (data not shown). The percentage of survivors with SCH was similar for all diagnoses (p=0.322, data not shown): leukemia, 35 of 162 (21.6%); NHL, 12 of 47 (25.5%); HD, 6 of 12 (50.0%); brain/naso, 11 of 43 (25.6%); WT/NB/abdomen, 23 of 79 (29.1%); and sarcoma/others, 17 of 73 (32.3%, data not shown).

Our findings showed that SCH was the most common thyroid hormone disturbance after cancer treatment (n=104). Owing to losses (n=12) during follow-up, our study group ultimately comprised 92 childhood cancer survivors with SCH; their characteristics are shown in [Table 1](#T1){ref-type="table"}. The number of male survivors was 61 (66.3%). The median ages at cancer diagnosis, cancer treatment completion, initial TFT, and final TFT were 3.97 (1.80--8.11), 6.00 (2.95--10.50), 9.75 (6.92--14.59), and 14.42 (10.82--19.15) years, respectively. The interval from completion of treatment to enrollment was 2.97 (2.33--4.95) years. The follow-up duration (initial TFT to final TFT) was 4.03 (2.15--5.78) years. The most common diagnosis was leukemia (n=32, 34.8%), followed by WT/NB/abdomen (n=21, 22.8%). Most survivors underwent chemotherapy (n=91, 98.9%), and 43 survivors received HSCT (46.7%).

Risk factors for persistent SCH: demographic findings
-----------------------------------------------------

Sixty-two survivors with SCH regained normal thyroid function more than 2 years after cancer treatment completion (the normalized group), whereas 30 did not (the persistent group). There were no differences in sex or any time variables (age at diagnosis or age at cancer treatment completion) between the normalized and persistent groups. There were, however, significant differences in terms of cancer type: leukemia (75.0%), WT/NB/abdomen (85.7%), and sarcoma/others (73.3%) were more common in the normalized group, whereas brain/naso (87.5%) and HD (66.7%) were more common in the persistent group. The fT4 levels were statistically similar in all survivors regardless of cancer type (*p*=0.176) ([Table 2](#T2){ref-type="table"}). TSH levels were significantly higher in survivors of brain/naso cancer than in survivors of the other cancer types (*p*=0.010). As for the treatment modality, fT4 was significantly higher in patients treated with HSCT than in those without HSCT (*p*=0.021), and fT4 was significantly lower in patients treated with radiation (*p*=0.044); however, the fT4 levels in all groups were within the normal range.

The initial TSH level was significantly higher in the persistent group than in the normalized group (7.71 mU/L vs. 4.86 mU/L; *p*=0.001 via Mann-Whitney U-test, data not shown). In the normalized group, the TSH level was significantly lower at the final follow-up than at the initial follow-up (2.88 mU/L vs. 4.86 mU/L; *p*\<0.001 via Wilcoxon signed rank test) ([Table 3](#T3){ref-type="table"}). The fT4 level was significantly higher at the initial follow-up than at the final follow-up (1.18 ng/dL vs. 1.07 ng/dL; *p*=0.008 via Wilcoxon signed rank test); however, all were in the normal range. In the persistent group, the TSH level was also lower at the final follow-up than at the initial follow-up (4.70 mU/L vs. 7.71 mU/L; *p*\<0.001 via Wilcoxon signed rank test).

In the persistent SCH group, 23 (76.7%) survivors received thyroid hormone replacement therapy. The mean TSH levels tended to be higher in the replacement group than in the non-replacement group, though not significant \[8.79 (5.46--12.71) mU/L vs. 6.27 (4.90--7.12) mU/L; *p*=0.149 via Mann-Whitney U-test\], and fT4 levels were not different \[1.11 (0.95--1.28) ng/dL vs. 1.09 (0.94--1.20) ng/dL; *p*=0.756 via Mann-Whitney U-test, data not shown\]. Survivors with good clinical status did not receive hormone replacement therapy, and their TSH level did not exceed 10 mU/L throughout the follow-up period.

Risk factors for persistent SCH: treatment factors
--------------------------------------------------

More survivors treated with radiation than without radiation showed persistent SCH (21 of 48, 43.8% vs. 9 of 44, 20.5%; *p*=0.017); the numbers of survivors previously receiving HSCT (*p*=0.378) or chemotherapy (*p*=0.326) were similar in both groups ([Table 1](#T1){ref-type="table"}). There were no group differences in the types of chemotherapeutic agents used with two exceptions: more survivors showed normalized SCH when treated with enzyme (e.g., L-asparaginase) than those treated without enzyme \[21 of 25 (84.0%) vs. 41 of 67 (61.2%); *p*=0.038\], whereas epipodophyllotoxin usage tended to be higher in the persistent group \[25 of 63 (38.1%) vs. 5 of 29 (20.7%); *p*=0.098\] ([Table 4](#T4){ref-type="table"}).

Radiation doses to the head region were significantly higher in the persistent group (2394±2469 cGy) than in the normalized group (894±1591 cGy; *p*=0.003), as were doses to the spine region (1319±1603 cGy vs. 462±921 cGy; *p*=0.001) ([Table 5](#T5){ref-type="table"}). Sixteen of the 37 (43.2%) survivors who had received head radiation ≥1800 cGy still had SCH at the final follow-up. In contrast, all four survivors (100%) who had received head radiation of \<1800 cGy returned to normal at the final follow-up (*p*=0.031, data not shown).

Radiation doses to the neck region were also higher in the persistent group than in the normalized group, although the difference was not significant (626±1468 cGy vs. 115±357 cGy; *p*=0.086) ([Table 5](#T5){ref-type="table"}). All of the four survivors who had received neck radiation ≥1500 cGy still showed SCH at the final follow-up. Seven of the nine survivors (77.8%) who had received neck radiation \<1500 cGy recovered normal thyroid function (*p*=0.009, data not shown). The total radiation dose per survivor was higher in the persistent group than in the normalized group (2883±2304 cGy vs. 1266±1707 cGy; *p*=0.001) ([Table 5](#T5){ref-type="table"}).

Time trend of thyroid function normalization
--------------------------------------------

The median interval from time of cancer treatment completion to time of normalization of thyroid function was 8.84 years (95% confidence interval, 7.10--10.58 years). When the survivors were split into three cancer type groups (brain tumor survivors, lymphoma survivors, and survivors of other cancers), there was a tendency of difference in the normalized proportion of SCH among the three groups (*p*=0.094) ([Fig. 1](#F1){ref-type="fig"}). Brain tumor survivors did not regain normal thyroid function during the follow-up compared to the survivors in the other groups (*p*=0.039).

Multivariable analysis of the risk factors for persistent SCH
-------------------------------------------------------------

Lymphoma (odds ratio, 6.71; *p*=0.011), and brain/naso (odds ratio, 15.35; *p*=0.039) were significant risk factors for persistent SCH when compared to other tumors as a reference ([Table 6](#T6){ref-type="table"}). A head radiation dose of ≥1800 cGy was also a significant risk factor (odds ratio, 3.78; *p*=0.039). Sex, HSCT, type of chemotherapeutic agent, and neck radiation dose ≥1500 were not significant risk factors.

DISCUSSION
==========

Primary hypothyroidism is caused by direct damage to the thyroid gland and is categorized as SCH or, if more severe, overt hypothyroidism. Central hypothyroidism is caused by damage to the hypothalamus-pituitary gland axis and can result in loss of endocrine function. In our study, SCH was the most common thyroid disease after treatment of childhood cancer (104 of 112 survivors, 92.9%). Development of SCH during the follow-up period was unrelated to the previous cancer type. However, the percentage of survivors who regained a euthyroid status differed according to cancer type and treatment. Our aim was to identify survivors at risk for persistent SCH and to suggest a watchful waiting strategy for the normalized group and an early therapy for the persistent group.

Diagnosis of SCH is based on laboratory findings. Most patients with SCH show no symptoms or signs. Some present with non-specific symptoms such as poor quality of life, anxiety, depression, fatigue, or constipation.[@B15] The prevalence of SCH ranges from 1% to 12.4% in the general population.[@B10] Other estimates are 4.3% (the National Health and Examination Survey III) and 5.4--17.3% (large studies of thyroid dysfunctions in Koreans 17 years of age or older).[@B16][@B17] Prevalence tends to increase as age increases.[@B17] There are no studies on SCH prevalence in Korean children.

TSH levels return to normal in 15--65% of untreated individuals 1--6 years after one-time elevations[@B18][@B19] and in \>50% of individuals with increased or decreased levels.[@B19] However, a significant proportion of adult patients with SCH progress to overt hypothyroidism. The rate of progression to overt hypothyroidism was 1--4% per year in one study and 2.9% per 5 years in another.[@B15][@B19] In a prospective study with a mean observation time of 9 years, 30--50% of female patients with SCH developed overt hypothyroidism, depending on clinical risk factors.[@B20]

The clinical consequences of SCH are controversial. In a meta-analysis of 55287 subjects, the risk of coronary heart disease and mortality increased as TSH concentration increased.[@B21] The hazard ratio in the meta-analysis was 1.89 (95% confidence interval, 1.28--2.80) at 10 mU/L TSH. Conversely, two prospective studies found no association between SCH and the outcomes of patients with cardiovascular disease.[@B22][@B23] Other consequences of SCH include non-alcoholic fatty liver disease[@B24] and, although not observed in all studies, psychiatric manifestations such as depression, anxiety, and cognitive dysfunction.[@B25]

Endocrinologists recommend thyroid hormone replacement for patients with TSH concentrations of \>10 mU/L and routine surveillance for patients with TSH concentrations of ≤10 mU/L.[@B8][@B9] Replacement therapy is sometimes advised for people aged less than 65 years, as their cardiovascular risks are greater than those of people aged 65 years or more.[@B15]

SCH is less prevalent in children than in adults. Although insufficient, data thus far suggest that SCH occurs in 1.7--9.5% of otherwise normal children.[@B10] The natural course of SCH in childhood has not been well studied. In a recent meta-analysis, only nine relevant studies could be evaluated,[@B6] most of which included only a small number of subjects. An exception was a large-scale retrospective study conducted in Israel; however, most of its subjects had autoimmune thyroiditis.[@B11] The rate of recovery in the meta-analysis was 21.9--50%, and progression to overt hypothyroidism was 0--28.8%.[@B6] In the Israeli study, SCH prevalence was 3.3% (n=3938), and 70.1% of patients with SCH had normal TSH levels in subsequent tests.[@B11]

Thyroid dysfunction in childhood cancer survivors is a well-known late effect.[@B3][@B7][@B26] Primary hypothyroidism is the most common abnormal thyroid-related response to thyroid irradiation.[@B4] Risk factors for hypothyroidism include neck, craniospinal, and total body irradiation[@B3][@B4] yet apparently not chemotherapy.[@B4][@B13] Compared with primary overt hypothyroidism, SCH in childhood cancer survivors is less understood. The percentage of long-term survivors of Hodgkin lymphoma (n=55) who develop SCH is 20%.

Data on the natural history of SCH in childhood cancer survivors are limited. A previous study showed impaired thyroid function in 24% of survivors (71 of 291) during a median follow-up period of 6.1 years[@B13] yet did not address SCH status after this time. Ishiguro, et al.[@B12] found that 26.5% of patients (39 of 147) who underwent bone marrow transplantation developed SCH. Their TSH levels decreased from the upper normal range 8 years after bone marrow transplantation to the mid to normal range thereafter. However, the proportion of patients who recovered from SCH was not presented.

In our study, 12 (2.8%) of the 423 childhood cancer survivors had overt hypothyroidism, mainly the brain/naso survivors. SCH was the most common thyroid dysfunction in the 423 survivors (104, 24.6%), as well as in the 123 survivors with thyroid abnormalities (104, 84.5%). Among the study cohort (n=92), 67.4% of patients with SCH regained normal thyroid function. This result is similar to those in other pediatric studies on patients with autoimmune disease or healthy thyroids.[@B6][@B11] In our study, 60--85% of leukemia, NHL, and WT/NB/abdomen survivors regained normal thyroid function, whereas only 12.5--33.3% of brain/naso and HD survivors did so; this difference was significant (*p*=0.002) ([Table 2](#T2){ref-type="table"}). Although the proportion of leukemia survivors with SCH was substantial (21.6%, which was much higher than in a normal pediatric cohort), most exhibited normalized thyroid function at the final follow-up. The percentages of brain/naso survivors with SCH or overt hypothyroidism were 25.6% (11 of 43) and 20.9% (9 of 43), respectively; however, most of them did not recover a euthyroid status. Collectively, these data show that SCH is frequently found in childhood cancer survivors regardless of cancer type. Leukemia and WT/NB/abdomen survivors can be managed without further treatment, whereas brain/naso survivors should receive thyroid hormone replacement as soon as possible, even if they have SCH rather than overt hypothyroidism.

The risk factors for persistent SCH are similar to those for overt hypothyroidism as reported in previous studies.[@B4][@B5] However, the data on the dose-volume effect for the development of SCH are generally lacking. Our multivariable analysis confirmed that brain/naso tumors, lymphoma, and head radiation doses ≥1800 cGy were all significant risk factors for SCH. Brain tumor survivors have an increased risk of endocrine, psychiatric, cognitive, neurological, and developmental disorders owing to previous radiotherapy.[@B3][@B4] The threshold dose for pituitary-hypothalamus hypothyroidism was 5000 cGy in the studies on the cranial irradiation.[@B27][@B28][@B29] When the radiation dose to the pituitary gland was increased from 2000 to 4500 cGy, the risk of hypothyroidism increased from 9% to 52%.[@B29] As for direct thyroid radiation, the thresholds are less clear; however, radiation doses greater than 3000--4000 cGy are generally accepted as a threshold.[@B29][@B30] Nevertheless, the threshold for SCH has not yet been established. A large study on the general health status of cancer survivors reported that exposure of the hypothalamuspituitary axis to ≥1800 cGy disrupted this axis in \>50% of survivors.[@B31] However, it regarded all physical and laboratory findings including growth, pubertal progress, menstrual history, insulin-like growth factor 1 (IGF-1), cortisol, estradiol, TSH, and fT4 by screening studies as outcome measurements and did not specify the kind, proportion, or severity of axis disruption.[@B31] Therefore, the radiation dose for inducing SCH could not be confirmed. In this study, radiation exposure of 1800 cGy or more to the head region posed the risk of persistent SCH, and this dose was lower than the dose causing overt hypothyroidism.

Whether cancer survivors who develop SCH during follow-up should receive treatment is an unanswered question. Our study provides suggestions based on the presence of risk factors. However, it had several limitations. First, the study cohort was prospective, whereas the analysis was retrospective. Second, follow-ups regularly occurred every 6 months; however, several survivors were lost during follow-up. Third, the duration of the follow-up was 4.2 years, yet the range was variable. Fourth, certain cancer types had an insufficient number of survivors for analysis. Fifth, survivors with normal thyroid function at the initial follow-up did not receive additional TFTs in compliance with the Korean health insurance policy. Sixth, thyroid autoantibodies as a risk factor for progression to thyroid disease were not examined owing to the retrospective nature of our analysis. Despite these limitations, our study is one of the few studies on SCH in childhood cancer survivors, and it provides new data for Korean survivors. We showed that a substantial number of leukemia and WT/NB/abdomen survivors developed SCH, and our follow-up data described the natural course of SCH in survivors.

In conclusion, SCH is a frequent late effect in childhood cancer survivors. Most leukemia and WT/NB/abdomen survivors with SCH recovered spontaneously. There was an increased risk of persistent SCH in survivors with brain/naso, lymphoma, or head radiation at doses ≥1800 cGy.
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###### Demographic Characteristics of Patients with Persistent Subclinical Hypothyroidism (SCH)

![](ymj-57-915-i001)

  Characteristic                               Normalized SCH (n=62, 67.4%)   Persistent SCH (n=30, 32.6%)   Total (n=92)           *p* value
  -------------------------------------------- ------------------------------ ------------------------------ ---------------------- -----------
  Sex (male:female)                            39 (62.9):23 (37.1)            22 (73.3):8 (26.7)             61 (66.3):31 (33.7)    0.321
  Age at diagnosis (yr)                        3.88 (1.66--7.96)              4.70 (1.80--11.47)             3.97 (1.80--8.11)      0.355
  Age at completion (yr)                       5.95 (2.73--9.76)              6.11 (3.20--12.10)             6.00 (2.95--10.50)     0.373
  Age at initial study (yr)                    9.75 (7.30--13.92)             9.62 (6.18--18.83)             9.75 (6.92--14.59)     0.748
  Time from completion to initial study (yr)   3.48 (2.37--5.18)              2.47 (2.18--3.56)              2.97 (2.33--4.95)      0.051
  Age at final study (yr)                      14.24 (10.83--17.22)           15.54 (10.55--21.72)           14.42 (10.82--19.15)   0.283
  Follow-up period (yr)                        3.80 (2.01--5.51)              4.42 (3.10--6.54)              4.03 (2.15--5.78)      0.142
  Diagnosis, n (%)                                                                                                                  0.002
   Leukemia                                    24 (75.0)                      8 (25.0)                       32 (34.8)              
   NHL                                         6 (60.0)                       4 (40.0)                       10 (10.9)              
   HD                                          2 (33.3)                       4 (66.7)                       6 (6.5)                
   Brain/naso                                  1 (12.5)                       7 (87.5)                       8 (8.7)                
   WT/NB/abdomen                               18 (85.7)                      3 (14.3)                       21 (22.8)              
   Sarcoma/others                              11 (73.3)                      4 (26.7)                       15 (16.3)              
  Treatment modality, n (%)                                                                                                         
   HSCT                                                                                                                             0.378
    Yes                                        27 (62.8)                      16 (37.2)                      43 (46.7)              
    No                                         35 (71.4)                      14 (28.6)                      49 (53.3)              
   Radiation                                                                                                                        0.017
    Yes                                        27 (56.3)                      21 (43.8)                      48 (52.2)              
    No                                         35 (79.5)                      9 (20.5)                       44 (47.8)              
   Chemotherapy                                                                                                                     0.326
    Yes                                        62 (68.1)                      29 (31.9)                      91 (98.9)              
    No                                         0 (0.0)                        1 (100)                        1 (1.1)                

NHL, non-Hodgkin leukemia; HD, Hodgkin disease; naso, nasopharyngeal; WT, Wilms tumor; NB, neuroblastoma; HSCT, hematopoietic stem cell transplantation.

###### Thyroid Function at 2 Years after Cancer Treatment Completion

![](ymj-57-915-i002)

  Characteristic         FreeT4 (ng/dL)      *p* value^\*^   TSH (mU/L)            *p* value^\*^
  ---------------------- ------------------- --------------- --------------------- ---------------
  Sex (n)                                    0.650                                 0.617
   Male (61)             1.15 (1.03--1.31)                   5.36 (4.00--8.25)     
   Female (31)           1.19 (0.98--1.31)                   5.44 (4.51--7.91)     
  Diagnosis (n)                              0.176                                 0.010
   Leukemia (32)         1.18 (0.94--1.35)                   5.45 (4.19--7.71)     
   NHL (10)              1.20 (1.11--1.39)                   4.60 (2.86--5.62)     
   HD (6)                1.03 (0.93--1.36)                   4.82 (3.55--6.68)     
   Brain/naso (8)        0.96 (0.92--1.11)                   12.27 (9.16--14.22)   
   WT/NB/abdomen (21)    1.18 (1.10--1.37)                   5.44 (4.69--10.02)    
   Sarcoma/others (15)   1.14 (1.04--1.26)                   5.29 (4.14--6.52)     
  Treatment modality                                                               
   HSCT (n)                                  0.021                                 0.837
    Yes (43)             1.20 (1.06--1.38)                   5.48 (4.20--8.35)     
    No (49)              1.11 (0.98--1.25)                   5.26 (4.30--7.62)     
   Radiation                                 0.044                                 0.275
    Yes (48)             1.11 (0.96--1.21)                   5.68 (4.05--9.09)     
    No (44)              1.23 (1.07--1.35)                   4.90 (4.26--7.63)     
   Chemotherapy                              \-                                    \-
    Yes (91)             1.17 (1.02--1.31)                   5.35 (4.24--7.88)     
    No (1)               \-                                  \-                    

TSH, thyroid-stimulating hormone; NHL, non-Hodgkin leukemia; HD, Hodgkin disease; naso, nasopharyngeal; WT, Wilms tumor; NB, neuroblastoma; HSCT, hematopoietic stem cell transplantation.

^\*^Tested by Mann-Whitney U-test or Kruskal Wallis test.

###### Change of Thyroid Function during Follow-Up

![](ymj-57-915-i003)

                   Normalized SCH (n=62, 67.4%)   *p* value^†^        Persistent SCH (n=30, 32.6%)   *p* value^†^                             
  ---------------- ------------------------------ ------------------- ------------------------------ -------------------- ------------------- ---------
  FreeT4 (ng/dL)   1.18 (1.06--1.32)              1.07 (0.97--1.22)   0.008                          1.11 (0.94--1.25)    1.11 (0.98--1.22)   0.847
  TSH (mU/L)       4.86 (4.18--6.35)              2.88 (1.90--3.65)   \<0.001                        7.71 (5.18--12.27)   4.70 (2.32--6.62)   \<0.001

SCH, subclinical hypothyroidism; TSH, thyroid-stimulating hormone.

^\*^Initial means the time point of 2 years after cancer treatment completion, ^†^Tested via Wilcoxon signed rank test.

###### Thyroid Function According to Chemotherapeutic Agent
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                       Use         Normalized (%)   Persistent (%)   Total (%)   *p* value
  -------------------- ----------- ---------------- ---------------- ----------- -----------
  Corticosteroid       \-          32 (69.6)        14 (30.4)        46 (50.0)   0.656
  \+                   30 (65.2)   16 (34.8)        46 (50.0)                    
  Heavy metal          \-          41 (73.2)        15 (26.8)        56 (60.9)   0.137
  \+                   21 (58.3)   15 (41.7)        36 (39.1)                    
  Alkylating           \-          13 (65.0)        7 (35.0)         20 (21.7)   0.797
  \+                   49 (68.1)   23 (31.9)        72 (78.3)                    
  Anthracycline        \-          17 (58.6)        12 (41.4)        29 (31.5)   0.223
  \+                   45 (71.4)   18 (28.6)        63 (68.5)                    
  Antibiotic           \-          55 (68.8)        25 (31.3)        80 (87.0)   0.518
  \+                   7 (58.3)    5 (41.7)         12 (13.0)                    
  Antimetabolite       \-          27 (64.3)        15 (35.7)        42 (45.7)   0.560
  \+                   35 (70.0)   15 (30.0)        50 (54.3)                    
  Vinca alkaloid       \-          11 (68.8)        5 (31.3)         16 (17.4)   0.899
  \+                   51 (67.1)   25 (32.9)        76 (82.6)                    
  Epipodophyllotoxin   \-          23 (79.3)        5 (20.7)         29 (31.5)   0.098
  \+                   39 (61.9)   25 (38.1)        63 (68.5)                    
  Enzyme               \-          41 (61.2)        26 (38.8)        67 (100)    0.038
  \+                   21 (84.0)   4 (16.0)         25 (100)                     

###### Thyroid Function According to Radiation Site and Dose

![](ymj-57-915-i005)

  Radiation site                      Radiation dose (cGy, mean±SD)   *p* value     
  ----------------------------------- ------------------------------- ------------- ---------
  Head                                893.5±1591.1                    2394±2468.8   0.003
  Neck                                115.2±357.4                     626±1467.7    0.086
  Chest                               196±563.9                       260±869.2     0.841
  Abdomen                             302.6±836.9                     323±776.6     0.535
  Extremity                           220±621.6                       110±338.7     0.882
  Testis                              115.2±357.4                     110±338.7     \>0.999
  Spine                               462.1±920.7                     1319±1603     0.001
  Total radiation dose per survivor   1266.3±1707                     2883±2303.8   0.001

SCH, subclinical hypothyroidism.

###### Multivariable Analysis of Risk Factors for Persistent Subclinical Hypothyroidism

![](ymj-57-915-i006)

                         Odds ratio (95% CI)    *p* value
  ---------------------- ---------------------- -----------
  Sex                                           
   Female                0.80 (0.24--2.70)      0.716
  HSCT                                          
   Yes                   3.38 (0.93--12.36)     0.065
  Chemotherapy                                  
   Enzymes               0.26 (0.054--1.22)     0.087
   Epipodophyllotoxins   0.92 (0.21--3.92)      0.905
  Age at diagnosis                              
   \>10 years            0.85 (0.19--3.87)      0.838
  Diagnosis                                     
   Other tumors^\*^      1                      
   Lymphoma              6.71 (1.16--28.92)     0.011
   Brain/naso            15.35 (1.15--204.65)   0.039
  Head radiation                                
   Dose ≥1800 cGy        3.78 (1.07--13.30)     0.039
  Neck radiation                                
   Dose ≥1500 cGy        \-                     0.999

HSCT, hematopoietic stem cell transplantation; naso, nasopharyngeal; CI, confidence interval.

^\*^Other tumors included Wilms tumor, neuroblastoma, abdomen tumors, sarcoma, and other cancer types.
